Coherus Oncology (CHRS) Cash from Financing Activities (2014 - 2026)

Coherus Oncology's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $53.6 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 20399.24% year-over-year to $53.6 million; the TTM figure through Mar 2026 stood at -$219.9 million (down 16.86% YoY), while the FY2025 annual figure was -$273.7 million, down 46.39% from the prior year.
• Cash from Financing Activities came in at $53.6 million for Q1 2026 at Coherus Oncology, up from $8.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $54.3 million in Q2 2023 to a low of -$281.5 million in Q2 2025.
• A 5-year average of -$16.7 million and a median of $721000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 445.93% in 2024 and soared 20399.24% in 2026, its largest moves.
• Coherus Oncology's Cash from Financing Activities stood at $6.6 million in 2022, then plunged by 94.45% to $366000.0 in 2023, then plunged by 36.89% to $231000.0 in 2024, then jumped by 3398.27% to $8.1 million in 2025, then jumped by 563.16% to $53.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $53.6 million, $8.1 million, and $2000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison